Camurus AB (publ) (CAMRF)
USD 59.98
(0.01%)
USD 59.98
(0.01%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.06 Billion SEK | 35.72% |
| 2022 | 781.81 Million SEK | 24.58% |
| 2021 | 627.57 Million SEK | 23.71% |
| 2020 | 507.28 Million SEK | 14.66% |
| 2019 | 442.4 Million SEK | 33.95% |
| 2018 | 330.27 Million SEK | 11.83% |
| 2017 | 295.32 Million SEK | 37.53% |
| 2016 | 214.73 Million SEK | -40.02% |
| 2015 | 358 Million SEK | 142.46% |
| 2014 | 147.65 Million SEK | 99.08% |
| 2013 | 74.17 Million SEK | 3.5% |
| 2012 | 71.66 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 324.47 Million SEK | 15.69% |
| 2024 Q1 | 280.45 Million SEK | -22.75% |
| 2023 Q3 | 247.94 Million SEK | -7.9% |
| 2023 FY | 1.06 Billion SEK | 35.72% |
| 2023 Q4 | 363.02 Million SEK | 46.42% |
| 2023 Q2 | 269.21 Million SEK | 48.81% |
| 2023 Q1 | 180.9 Million SEK | -18.45% |
| 2022 Q1 | 189.3 Million SEK | 8.44% |
| 2022 FY | 781.81 Million SEK | 24.58% |
| 2022 Q3 | 175.96 Million SEK | -9.62% |
| 2022 Q4 | 221.83 Million SEK | 26.07% |
| 2022 Q2 | 194.7 Million SEK | 2.85% |
| 2021 Q3 | 139.36 Million SEK | -21.3% |
| 2021 Q4 | 174.56 Million SEK | 25.26% |
| 2021 FY | 627.57 Million SEK | 23.71% |
| 2021 Q1 | 136.55 Million SEK | -22.42% |
| 2021 Q2 | 177.08 Million SEK | 29.68% |
| 2020 Q1 | 118.44 Million SEK | 7.72% |
| 2020 FY | 507.28 Million SEK | 14.66% |
| 2020 Q4 | 176.01 Million SEK | 55.76% |
| 2020 Q3 | 113 Million SEK | 13.21% |
| 2020 Q2 | 99.81 Million SEK | -15.73% |
| 2019 Q4 | 109.95 Million SEK | -2.51% |
| 2019 Q1 | 99.92 Million SEK | -7.15% |
| 2019 Q2 | 119.73 Million SEK | 19.82% |
| 2019 Q3 | 112.78 Million SEK | -5.8% |
| 2019 FY | 442.4 Million SEK | 33.95% |
| 2018 Q2 | 87.25 Million SEK | 46.59% |
| 2018 FY | 330.27 Million SEK | 11.83% |
| 2018 Q4 | 107.61 Million SEK | 41.82% |
| 2018 Q3 | 75.88 Million SEK | -13.03% |
| 2018 Q1 | 59.52 Million SEK | -15.59% |
| 2017 FY | 295.32 Million SEK | 37.53% |
| 2017 Q3 | 80.18 Million SEK | 5.34% |
| 2017 Q4 | 70.51 Million SEK | -12.07% |
| 2017 Q1 | 68.64 Million SEK | -5.25% |
| 2017 Q2 | 76.12 Million SEK | 10.89% |
| 2016 Q1 | 43.39 Million SEK | -42.9% |
| 2016 FY | 214.73 Million SEK | -40.02% |
| 2016 Q3 | 46.56 Million SEK | -9.44% |
| 2016 Q4 | 72.44 Million SEK | 55.6% |
| 2016 Q2 | 51.41 Million SEK | 18.49% |
| 2015 Q2 | 168.68 Million SEK | 271.28% |
| 2015 Q1 | 45.43 Million SEK | -10.14% |
| 2015 Q3 | 66.25 Million SEK | -60.72% |
| 2015 Q4 | 75.99 Million SEK | 14.71% |
| 2015 FY | 358 Million SEK | 142.46% |
| 2014 Q4 | 50.56 Million SEK | 40.38% |
| 2014 Q3 | 36.01 Million SEK | 0.0% |
| 2014 FY | 147.65 Million SEK | 99.08% |
| 2013 FY | 74.17 Million SEK | 3.5% |
| 2012 FY | 71.66 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 10.86 Million USD | -9664.351% |
| Skye Bioscience, Inc. | 13.54 Million USD | -7732.353% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | -2748.135% |
| Nascent Biotech, Inc. | 2.22 Million USD | -47485.183% |
| Qrons Inc. | 643.67 Thousand USD | -164748.519% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -255290.044% |
| Adynxx, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -20944.878% |
| BioStem Technologies, Inc. | 22.97 Million USD | -4518.503% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -114797.727% |
| CSL Limited | 3.44 Billion USD | 69.235% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | -1747.305% |
| Evofem Biosciences, Inc. | 29.55 Million USD | -3490.471% |
| Rebus Holdings, Inc. | 664 Thousand USD | -159703.012% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -79356.894% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -272277.98% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -6527.585% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | -1122.668% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -21476.063% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -405320.936% |
| SQZ Biotechnologies Company | 85.61 Million USD | -1139.318% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -36285.682% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -70550.024% |
| Mesoblast Limited | 5.9 Million USD | -17878.516% |
| Marizyme, Inc. | 19.23 Million USD | -5415.079% |
| Genus plc | 147.7 Million USD | -618.41% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -11986.385% |
| Pharming Group N.V. | 225.49 Million USD | -370.57% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -51693.304% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -78994.775% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -12624.451% |
| ContraFect Corporation | 56.88 Million USD | -1765.197% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -23968.291% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -71655.913% |
| IMV Inc. | 37.7 Million USD | -2713.88% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -37927.105% |
| MultiCell Technologies, Inc. | 567.42 USD | -187002825.523% |
| ONE Bio Corp. | 6.44 Million USD | -16366.632% |
| Accustem Sciences Inc. | 3.74 Million USD | -28222.833% |
| RVL Pharmaceuticals plc | 85.94 Million USD | -1134.617% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -199367.631% |
| Q BioMed Inc. | 3.43 Million USD | -30775.963% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | -4193.312% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -40283.753% |
| Biomind Labs Inc. | 994.18 Thousand USD | -106630.156% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | -968.247% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -60200.35% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -15694.725% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -56814.239% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 4244468.0% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -57722.184% |
| GB Sciences, Inc. | 1.42 Million USD | -74598.013% |
| Alpha Cognition Inc. | 9.7 Million USD | -10832.78% |
| HST Global, Inc. | 140.9 Thousand USD | -752944.206% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -94226.835% |
| Halberd Corporation | 74.84 Thousand USD | -1417676.115% |
| Enzolytics Inc. | 2.17 Million USD | -48584.955% |
| Agentix Corp. | 1.37 Million USD | -77252.824% |
| Resverlogix Corp. | 12.71 Million USD | -8247.168% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -28965.384% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 30.807% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -101537.165% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -44021.46% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -67085.148% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -31062.953% |
| AVAX Technologies, Inc. | 7.31 Million USD | -14415.098% |
| Zenith Capital Corp. | 8.94 Million USD | -11765.056% |
| Genscript Biotech Corporation | 825.34 Million USD | -28.564% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -6090778.824% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -43116.09% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -618580.069% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -55139.142% |
| Kadimastem Ltd | 2.41 Million USD | -43926.668% |
| Helix BioMedix, Inc. | 1.97 Million USD | -53706.983% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -584572.011% |
| LadRx Corporation | 3.81 Million USD | -27737.098% |
| Cell Source, Inc. | 4.32 Million USD | -24431.957% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -114797.727% |
| NovAccess Global Inc. | 2.46 Million USD | -42915.598% |
| Affymax, Inc. | 39.38 Million USD | -2594.084% |
| Itoco Inc. | 919.14 Thousand USD | -115343.625% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -24935.119% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -94725.022% |
| Mobile Lads Corp. | 554.54 Thousand USD | -191244.271% |
| CytoDyn Inc. | 18.05 Million USD | -5776.022% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -4215768.727% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -482043.604% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -74635.736% |
| SYBLEU INC | 160.87 Thousand USD | -659471.347% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -58319.882% |
| International Stem Cell Corporation | 5.27 Million USD | -20030.753% |
| Bioxytran, Inc. | 3.82 Million USD | -27676.209% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -2015575.696% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -5215905.506% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | -2825.859% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -65480.47% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -144102.437% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -34007.747% |
| Neutra Corp. | 243.82 Thousand USD | -435093.031% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -5978.318% |
| PureTech Health plc | 144.59 Million USD | -633.827% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | -5078.613% |
| IXICO plc | 4.7 Million USD | -22442.851% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -11961.976% |
| Gelesis Holdings, Inc. | 117.74 Million USD | -801.155% |
| CSL Limited | 3.89 Billion USD | 72.744% |
| Cellectis S.A. | 97.32 Million USD | -990.312% |